Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene Symbol | ERBB4 | ||||||||||
Synonyms | ALS19 | HER4 | p180erbB4 | ||||||||||
Gene Description | ERBB4, erb-b2 receptor tyrosine kinase 4, encodes HER4, an ERBB family member that plays a role in cell survival and differentiation (PMID: 12648466). ERBB4 activating mutations are frequent in melanoma and have been demonstrated in lung adenocarcinoma (PMID: 19718025, PMID: 26050618). | ||||||||||
|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02925234 | Phase II | Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | NLD | 0 |
NCT03065387 | Phase I | Everolimus + Neratinib Neratinib + Palbociclib Neratinib + Trametinib | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation | Active, not recruiting | USA | 0 |
NCT02372006 | Phase Ib/II | Afatinib | Trial of Afatinib in Pediatric Tumours | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 2 |
NCT03805841 | Phase II | TH-4000 | Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN) | Terminated | USA | CAN | 1 |